Bio-Gene Technology Limited

ASX:BGT Stock Report

Market Cap: AU$8.7m

Bio-Gene Technology Balance Sheet Health

Financial Health criteria checks 4/6

Bio-Gene Technology has a total shareholder equity of A$2.8M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$3.2M and A$368.4K respectively.

Key information

0%

Debt to equity ratio

AU$0

Debt

Interest coverage ration/a
CashAU$2.21m
EquityAU$2.79m
Total liabilitiesAU$368.45k
Total assetsAU$3.16m

Recent financial health updates

Recent updates

We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Feb 22
We're Hopeful That Bio-Gene Technology (ASX:BGT) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Oct 25
Here's Why We're Not Too Worried About Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Jun 20
Here's Why We're Not At All Concerned With Bio-Gene Technology's (ASX:BGT) Cash Burn Situation

Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

Apr 28
Bio-Gene Technology Limited (ASX:BGT) Is Expected To Breakeven In The Near Future

What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Jan 11
What We Learned About Bio-Gene Technology's (ASX:BGT) CEO Compensation

Financial Position Analysis

Short Term Liabilities: BGT's short term assets (A$2.9M) exceed its short term liabilities (A$345.9K).

Long Term Liabilities: BGT's short term assets (A$2.9M) exceed its long term liabilities (A$22.5K).


Debt to Equity History and Analysis

Debt Level: BGT is debt free.

Reducing Debt: BGT has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BGT has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: BGT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 7.5% each year


Discover healthy companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 12:12
End of Day Share Price 2024/12/30 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Bio-Gene Technology Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tom WaitePAC Partners Securities Pty. Ltd.